EP2547396A1 - Dispositif pédagogique non verbal incorporé pouvant être intégré à des applicateurs - Google Patents

Dispositif pédagogique non verbal incorporé pouvant être intégré à des applicateurs

Info

Publication number
EP2547396A1
EP2547396A1 EP10848088A EP10848088A EP2547396A1 EP 2547396 A1 EP2547396 A1 EP 2547396A1 EP 10848088 A EP10848088 A EP 10848088A EP 10848088 A EP10848088 A EP 10848088A EP 2547396 A1 EP2547396 A1 EP 2547396A1
Authority
EP
European Patent Office
Prior art keywords
applicator
active agent
skin
microdevice
applicator according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10848088A
Other languages
German (de)
English (en)
Other versions
EP2547396B1 (fr
EP2547396A4 (fr
Inventor
Bai Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomed Devices Inc
Original Assignee
Nanomed Devices Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomed Devices Inc filed Critical Nanomed Devices Inc
Publication of EP2547396A1 publication Critical patent/EP2547396A1/fr
Publication of EP2547396A4 publication Critical patent/EP2547396A4/fr
Application granted granted Critical
Publication of EP2547396B1 publication Critical patent/EP2547396B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/20—Surgical instruments, devices or methods, e.g. tourniquets for vaccinating or cleaning the skin previous to the vaccination
    • A61B17/205—Vaccinating by means of needles or other puncturing devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/422—Desensitising skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00017—Electrical control of surgical instruments
    • A61B2017/00115—Electrical control of surgical instruments with audible or visual output
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/06—Measuring instruments not otherwise provided for
    • A61B2090/064—Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension
    • A61B2090/065—Measuring instruments not otherwise provided for for measuring force, pressure or mechanical tension for measuring contact or contact pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/08—Accessories or related features not otherwise provided for
    • A61B2090/0803—Counting the number of times an instrument is used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/20—Holders specially adapted for surgical or diagnostic appliances or instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback

Definitions

  • the present subject matter relates to a built-in non-verbal compact instructional device integratable to an applicator having a microdevice for painlessly perforating the skin and optionally an active agent for application to the area of skin being perforated.
  • the microdevice of the applicator referred to herein can include microneedles, microneedle arrays, microblades, microblade arrays, microknives, microknife arrays, and Functional MicroArrays (FMAs).
  • Drugs are commonly administered in solid form through pills or capsules that can be orally taken. However, many biological drugs can not be administered this way because of degradation in the gastrointestinal tract and quick elimination by the liver.
  • Another common technique for administration of drugs in liquid form is through injection using a metal hypodermic needle that can cause significant pain and discomfort to patients.
  • a number of physical and chemical techniques including electroporation, laser ablation, ultrasound, thermal, iontophoresis and chemical enhancers have been explored to develop painless percutaneous drug delivery techniques. It was found that it is very difficult for molecules with a molecular weight higher than 500 or a diameter larger than 1 nm to penetrate normal human skin.
  • microneedles have been recently developed to disrupt the stratum corneum and facilitate the delivery of the active agents and ingredients to the epidermis. These active substances can then diffuse through the rest of the epidermis to the dermis to be absorbed by blood vessels and lymphatics. The substance absorbed can then get into the circulation system.
  • both topical and systemic delivery of drugs is possible. Since there are no nerves and blood vessels in the stratum corneum and epidermis, this is a minimally invasive, painless and blood-free method of drug delivery.
  • An additional advantage of this method when engineered for topical delivery of vaccines, can lead to enhanced inoculation effect because the epidermis is rich in antigen presenting cells and is a desired target for vaccine delivery.
  • U.S. Pat. No. 5,855,801 and U.S. Pat. No. 5,928,207 assigned to The Regents of the University of California taught a microneedle fabrication method similar to IC compatible neural recording arrays.
  • the disclosed microneedle arrays are typically linear arrays as they are in the plane of the silicon substrate surface.
  • Microneedles have also been fabricated by heating the glass tube and lengthening the heated part till the diameter of the tip is reduced to the desired range.
  • U.S. Pat. No. 6,503,231 by Prausnitz et al discloses a method for making out-of-the- plane porous or hollow microneedles. It either involves porous silicon formed by anodization of silicon or deals with sacrificial molds or selective removal of substrate materials to form fluidic conduits.
  • U.S. Pat. No. 6,51 1,463 by JDS Uniphase Corp. also teaches a method to fabricate the same.
  • U.S. Pat. No. 6,558,361 assigned to Nanopass Ltd. teaches a method for the manufacture of hollow microneedle arrays by removing a selective area of substrate material.
  • U.S. Pat. No. 6,603,987 assigned to Bayer Corp. also discloses a method to make a hollow microneedle patch. All these methods are trying to perform certain functions of the current hypodermic needles and create a miniaturized analog to perform drug delivery or extract body fluids without causing pain and discomfort.
  • U.S. application publication No. 2004/0199103 describes a single-step method of delivering an active agent using a "solid solution perforator" ("SSP") which incorporates an active agent in the SSP matrix material itself.
  • SSP solid solution perforator
  • the SSP perforates the skin and then the SSP biodegrades and dissolves to release the active agent through the skin.
  • the publication describes that the delivery of the active agent is initiated only after the SSP sufficiently degrades, and delivery is stopped once the SSP is removed from the skin.
  • U.S. application publication No. 2004/0241965 describes a method of making high aspect ratio electrode arrays comprised of solid metals. It involves the preparation of porous microchannel glass template, electrodeposition of metals in the microchannels, and final preparation of an electrode array following an electrodeposition.
  • the body of microelectrode is formed by electrodeposition method similar to those used in forming nanowires. Microneedles having hollow bodies also require a readily available active agent reservoir or conduit for providing subsequent injection delivery of an
  • microneedles whether they are in-the-plane or out-of-the- plane from the substrate material, are cumbersome and/or expensive.
  • the hollow microneedle arrays while their sizes are scaled down from conventional needles, are especially expensive to make and use because of complexity in the fabrication process and the difficulty in providing a readily available active agent reservoir or conduit for injecting an active agent.
  • the mechanical integrity of prior microneedles also suffers as their sizes become smaller and/or as they are made with readily biodegradable materials such as those preferred for use as solid solution perforators.
  • incorporating the prior art microneedles and arrays on an applicator device that can be easily used by any individual multiple times, and readily provide an active agent for multiple uses, is likely to be very cumbersome and expensive.
  • the FMA microdevice feature described herein has been shown to be effective for enhancing delivery of a variety of active agents, for example, as described in U.S. application publication Nos. 2008/0051695 and 2008/0214987. Also, for example, it has been established that FMA-enhanced delivery of lidocaine effectively manages pain as indicated in U.S. application publication No. 2007/060867, and as reported for a large clinical trial in Li et al., "Microneedle Pretreatment Improves Efficacy of Cutaneous Topical Anesthesia", Am. J. Emergency Med., 28: 130-134 (2010).
  • the present subject matter provides an applicator having a first region comprising a microdevice for perforating the skin and a second region comprising an active agent to be applied to the area of skin being perforated.
  • An applicator of the present subject matter having a microdevice for perforating the skin at a first region and an active agent for application to the skin stored in a first chamber at a second region.
  • the microdevice component can comprise a plurality of high-aspect-ratio microneedles, microneedle arrays, microblades, microblade arrays, microknives, microknife arrays, or combinations thereof.
  • the microdevice is also called a Functional MicroArray (FMA).
  • the microdevice portion of the applicator is useful for perforating the stratum corneum layer, the outer layer of skin, without significant pain or discomfort to a patient.
  • the microdevice is designed to permit percutaneous delivery of substances across the stratum corneum layer, the outer layer of skin, that is about 4-30 micron thick.
  • the microdevice is designed so that it generally does not penetrate to the depth of sensory nerves that detect pain or discomfort in the skin.
  • the length of the microdevice is less than 150 ⁇ .
  • the surface area of the microdevice ranges from 1mm 2 to 2500 mm 2 .
  • the density of microneedles, microblades, or microknives on the microdevice ranges from 20 per cm 2 to 20,000 per cm 2
  • the active agent stored in the applicator is applied to the area of skin being perforated by the microdevice. In many embodiments, the active agent is applied after the skin is perforated by the microdevice. In other embodiments, the active agent is applied to the area of skin being perforated before the skin is perforated by the microdevice.
  • the primary object of the present subject matter to provide an applicator that provides in a single unit the features for performing a two-step method for efficient and efficacious delivery of drug compounds, vaccines and active cosmetic substances through the skin.
  • the first step is the application of the microdevice on the applicator to the skin to generate a multiplicity of microchannels in the stratum corneum layer.
  • the length of the microdevice' s microneedles, microblades, and/or microknives is such that penetration depth does not reach the dermis layer to cause any pain or discomfort.
  • This delivery is called intraepidermal delivery that is difference from traditional transdermal drug delivery and needle injections.
  • the second step is to immediately remove the microdevice and apply one or more active substances to the area of skin perforated by the microdevice.
  • the active substance(s) are stored in the applicator in a reservoir and applied directly from the applicator to the area of skin perforated by the microdevice,
  • an occlusive layer is applied over the active agent that has been applied to the perforated area of skin.
  • an applicator for providing a safe, painless, and convenient method for percutaneous delivery of substances such as drugs, vaccines, and cosmetic compounds.
  • the applicator may optionally include one or more indicator features, or signals, for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin.
  • indicator features, or signals useful in this regard include a light signal, a sound signal, a vibration signal, a recorded counter signal, an electrically transmitted signal, an RF transmitted signal and combinations thereof.
  • the present applicator can also use one or more indicator features or signals to indicate that the microdevice has been applied to the skin and has stayed on the skin for a pre-determined period of time.
  • the present applicator can have a circuit to count how many times the applicator has been applied to the skin, wherein the one or more indicator features or signals can optionally change when a pre-determined number of applications is reached.
  • the applicator can be useful for providing an enhanced percutaneous delivery of an active agent, with minimal discomfort, for therapeutic or cosmetic treatment, such as, for example, topical treatment for acne, or other skin disorders, acne marks, hypigmentation, wrinkles, blemishes, etc.
  • the applicator can also be useful for providing improved systemic or localized delivery of an active agent, such as, for example, lidocaine, salicylic acid, benzoyl peroxide, azeleic acid and its derivatives, L-carnitine, insulin, botulinum toxin, vitamin C and its derivatives, arbutin, niacinamide etc.
  • the present subject matter relates to an applicator with at least one built-in non-verbal instructional device comprising:
  • a hollow body structure having a first end and a second end, and having an exterior surface and an interior surface;
  • said first end of said body structure having at least one built-in non-verbal instructional device to elicit correct behavior, rectify incorrect behavior and improve user compliance by producing instructional signals signifying one or more of
  • said second end of said body structure containing at least one element selected from the group consisting of at least one opening to allow dispensing of an active agent that can treat certain diseases; at least one opening to allow dispensing of pigments or inks to temporarily change the appearance of skin; a connector that attaches to a personal communication device, personal entertainment device, writing device, knife, scissors, clump, pen sharpener, key chain, magnetic bar, cartoon head, decoration object or a toy; and a solid end without any opening.
  • the present subject matter relates to an applicator with at least one built-in non-verbal instructional device comprising:
  • a hollow body structure having a first end and a second end, and having an exterior surface and an interior surface; said first end of said body structure comprising a microdevice for perforating only the skin's stratum comeum layer for intraepidermal delivery of active agents and at least one built-in non-verbal instructional device to elicit correct behavior, rectify incorrect behavior and improve user compliance by producing instructional signals signifying one or more of the number of applications, the force of each application to validate each application, and the duration of each application;
  • said second end of said body structure containing at least one element selected from the group consisting of at least one opening to allow dispensing of an active agent that can treat certain diseases; at least one opening to allow dispensing of pigments or inks to temporarily change the appearance of skin; a connector that attaches to a personal communication device, personal entertainment device, writing device, knife, scissors, clump, pen sharpener, key chain, magnetic bar, cartoon head, decoration object or a toy; and a solid end without any opening.
  • the present subject matter relates to an applicator with at least one built-in non-verbal instructional device comprising
  • a hollow body structure having a first end and a second end, and having an exterior surface and an interior surface;
  • said first end of said body structure comprising a microdevice for perforating only the skin's stratum corneum layer for intraepidermal delivery of active agents and at least one built-in non-verbal instructional device to elicit correct behavior, rectify incorrect behavior and improve user compliance by producing instructional signals signifying one or more of the number of applications, the force of each application to validate each application, and the duration of each application; said second end of said body structure comprising an active agent reservoir comprising at least one active agent; and an active agent applicator portion that provides for release of the active agent from the active agent reservoir.
  • the subject matter described herein advantageously provides a disposable multi-use applicator having both a microdevice for painlessly perforating the outer layer of skin and a reservoir of active agent for providing a two-step method of enhanced delivery of a therapeutic or cosmetic active agent combined in a single convenient, inexpensive, and pocket portable unit.
  • the ease of using a single applicator to perform the two-step method of enhanced delivery of a therapeutic or cosmetic active agent provides an added advantage for using the applicator described herein, and helps ensure patient compliance with treatment regimes requiring multiple repeated administrations over several days or weeks.
  • FIG. 1 is a schematic view of a first applicator embodiment showing an exploded view of all components.
  • This embodiment includes an optional signal feature for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin, the duration of application on the skin, the number of times the applicator has been activated etc.
  • FIG. 2 shows schematic views of the first applicator embodiment having a microdevice for painlessly perforating the outer layer of skin and a reservoir of active agent.
  • FIG. 3 shows a schematic view of the first applicator embodiment wherein the FMA microdevice moves the actuator arm when contacting the skin.
  • the actuator arm thereby contacts the pressure sensitive signal device which generates a signal when sufficient force is applied when contacting the skin with the microdevice to perforate the skin.
  • FIG. 4 is a schematic view of a second applicator embodiment showing an exploded view of all components.
  • This embodiment includes an optional signal feature for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin, the duration of application on the skin, the number of times the applicator has been activated etc.
  • FIG. 5 shows schematic views of the second applicator embodiment having a microdevice for painlessly perforating the outer layer of skin and a reservoir of active agent.
  • FIG. 6 shows scanning electron microscope micrographs of examples of two different microneedle arrays having different microneedle sizes and density of microneedles. These microneedle arrays are examples of those that may be found on an applicator described herein.
  • FIG. 7 is a perspective illustration showing the depth that the microdevice on the applicator perforates into the skin relative to the stratum corneum (SC), epidermis (Epi), and dermis (Derm), and the subsequent delivery of active agent applied to the area of skin that was perforated via microchannels generated by the microdevice.
  • SC stratum corneum
  • Epi epidermis
  • Derm dermis
  • FIG 8. The LC profiles of cumulative amount vs. time using skins of different species with and without FMA-assisted delivery. Mean ⁇ S.D., n ⁇ 3. Each donor concentration was 640 mg/mL.
  • FIG 10. Diffusion profiles of the gels with different type of carbomer polymers on the release of LC across porcine ear skin by FMA-treated, mean ⁇ S.D., n 4.
  • FIG. 12 shows a cross-sectional view of the applicator in a package with one side of the applicator over a depression.
  • FIG. 13 provides a 3D illustration of the applicator in its packaged box.
  • the present subject matter provides an applicator having a first region comprising a microdevice for perforating the skin and a second region comprising an active agent to be applied to the area of skin being perforated.
  • the microdevice component can comprise a plurality of high-aspect-ratio microneedles, microneedle arrays, microblades, microblade arrays, microknives, microknife arrays, or combinations thereof.
  • the microdevice is also called a Functional MicroArray (FMA).
  • FMA Functional MicroArray
  • the present subject matter also provides methods of using the applicator for percutaneous delivery of drugs, vaccines, diagnostic agents and cosmetic substances for treating, preventing, or ameliorating a medical or cosmetic condition of a mammal such as a human being.
  • the applicators described herein provide in a single unit features for performing a two-step method for efficient and efficacious delivery of drug compounds, vaccines and active cosmetic substances through the skin.
  • the first step is the application of the microdevice on the applicator to the skin to generate a multiplicity of microchannels in the stratum corneum layer.
  • the length of the microdevice' s microneedles, microblades, and/or microknives is such that penetration depth does not reach the dermis layer to cause any pain or discomfort.
  • This delivery is called intraepidermal delivery that is difference from traditional transdermal drug delivery and needle injections. Accordingly, for intraepidermal drug delivery (LED) as described herein, it is important to use a microdevice or FMA having a length of less than 150 ⁇ so as not to penetrate to the depth of sensory nerves that detect pain or discomfort in the skin.
  • the second step is to immediately remove the microdevice and apply one or more active substances to the area of skin perforated by the microdevice.
  • the active substance(s) are stored in the applicator in a reservoir and applied directly from the applicator to the area of skin perforated by the microdevice,
  • an occlusive layer is applied over the active agent that has been applied to the perforated area of skin.
  • an applicator for providing a safe, painless, and convenient method for percutaneous delivery of substances such as drugs, vaccines, and cosmetic compounds.
  • Skin has a biological barrier called stratum corneum in its outer layer. This layer of about 20 microns thick prevents most of the molecules from penetrating through the skin.
  • the layer below the stratum corneum is called viable epidermis.
  • Epidermis is between 50 to 100 micron thick.
  • the viable epidermis layer has no blood vessels and the molecules in this layer can be transported to and from the dermis, a layer under the viable epidermis, which is between 1 to 3 mm thick. There are blood vessels, lymphatics and nerves in the dermis layer.
  • the microdevice has microneedles, microblades, and/or microknives having a length that will perforate the stratum corneum and terminate in the epidermis layer, thus not reaching the dermis layer.
  • a skin patch is only able to deliver drug molecules of less than 500 Da.
  • these small molecules are typically limited to hydrophobic drugs.
  • Requirement of Delivery of Drugs, Vaccines and Cosmetic Substances Successful percutaneous delivery of therapeutic drugs, vaccines and cosmetic substances needs a way to transport molecules, especially large molecules, through the skin barrier, i.e., the stratum corneum.
  • the substance can be delivered into the skin in any form acceptable to pharmaceutical requirements, but a gel formulation is preferred to achieve controlled release of active ingredients.
  • Other topical delivery formulations such as lotions, creams, ointments, solutions, foams, etc., can be used as well.
  • the microdevice described herein can be used for effective percutaneous delivery of an agent.
  • the microdevice can be a microdevice array comprising a plurality of microstructures formed of a metallic, semi-conductor, glass, ceramic, or polymeric material.
  • the microdevice can be one or more microneedles, microknives, or microblades.
  • the microdevice comprises microstructures having a nanoscale tip or edge and a microscale body.
  • Aspect-ratio is defined herein as the ratio of the depth or height of a structure to its lateral dimension. High-aspect-ratio microstructures typically have an aspect ratio higher than about 5: 1 and they may be useful for a variety of purposes.
  • the tip of the microneedle or the edge of the microblade and microknife needs to be sharp in order to lower the insertion force, while the body of the microdevice should be long enough to allow it to completely penetrate the stratum corneum.
  • a typical size of the needle tip or width of the edge on microblades and microknives is smaller than 10 microns, preferably smaller than 5 microns and the height of the microdevices is higher than 20 microns, preferably higher than 50 microns.
  • microdevices of the present subject matter generally comprise high aspect ratio microneedles, microblades, or microknives for perforating the skin and thus facilitating delivery of an active agent through the resulting perforations in the skin.
  • the microdevice in the applicator comprises microneedles, microblades, or microknives having a length ranging from 4 to 500 microns. In one embodiment, the microdevice in the applicator comprises microneedles, microblades, or microknives having a length ranging from 10 to 200 microns. In another embodiment, the microdevice in the applicator comprises microneedles, microblades, or microknives having a length ranging from 20 to 100 microns.
  • the applicator described herein can have a volume of at least 0.1 cm 3 .
  • This minimum volume can be inclusive of any built-in non-verbal instructional devices or active agents contained therein.
  • the applicator has a volume of 0.1 to 10 cm 3 . -
  • the microneedle devices disclosed herein can contain one or more microneedles.
  • the length of the microneedle is typically in the range of 20-500 microns, sufficient to pierce through the outer skin barrier layer and deliver molecules to viable epidermis or even deeper.
  • the microneedles have a length that does not reach into the dermis where blood vessels and nerves might be disturbed.
  • the diameter of a single microneedle is typically in the range of 30-300 microns with a sharp tip of less than 10 microns to cause little discomfort to the patients while maintaining mechanical integrity.
  • the needle tip is less than 2 microns and the height of the needle shaft is about 100 microns.
  • the aspect ratio is 50: 1.
  • the angle of the tip is between 30 to 75 degrees, typically between 38-72 degree.
  • FIG. 6 shows a micrograph of microneedle arrays fabricated by this method with a zoom in view of a single microneedle that has a base diameter of about 80 microns.
  • the inner diameter of the needle tip is about 10 microns and the height of the needle is about 1200 microns to allow sufficient extraction of body fluids.
  • the aspect ratio is preferably 120:1.
  • the microblades and microknives disclosed herein can contain one or more blades or knives.
  • the sharp edge of these devices is below 10 microns wide and the height of the body is more than 100 microns. In a preferred embodiment of the current subject matter, the edge is below 3 microns and the body height is about 150 microns.
  • the skin contact area is about (0.003 mm x 1 mm) for each microblade or microknife.
  • the leading angle of the blade edge is between 30 to 75 degrees, preferably between 38-72 degrees.
  • the devices can be made of many different materials or their combinations, including metals, ceramics, polymers and glass.
  • the materials are titanium, stainless steel, nickel, alloy of nickel-iron, silicon, silicon oxide, glass, polymethyl methacrylate (PMMA), polyaryletherketone, nylon, PET, poly(lactic acid), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), polycarbonate, and polystyrene. It should have enough mechanical strength to penetrate skin without break and buckle while ensuring delivery of drugs, or collection of biological fluids.
  • Microchannels can be embedded in microdevices to allow flexible manipulation of microfluidics and connect microneedles to other functional blocks such as drug reservoirs.
  • Microchannels can be made of many different materials or their combinations, including metals, ceramics, polymers and glass.
  • the device described herein can be used for percutaneous delivery of an agent to treat, prevent, or ameliorate a body condition in need of treatment.
  • the method generally includes treating a skin site of delivery with a microdevice described herein, and delivery of an agent to the body of a mammal (e.g., a user or patient).
  • the applicator is used so that one or more active agents is applied to the area of skin being perforated either immediately before the area of skin is perforated by the microdevice, or immediately after the area of skin is perforated by the microdevice.
  • the applicator is used so that the microdevice is immediately removed from the skin after the microdevice perforates the skin.
  • the applicator can be used to apply the microdevice to the skin a multiple number of times during a single treatment. By applying the applicator more than once during a single treatment, the applicator may be used to perforate the skin over a larger surface area, or at multiple different locations on the patient.
  • a second active agent can be applied to the area of skin being treated by the applicator.
  • This second agent may be contained in a second active agent chamber in the applicator.
  • the second active agent is separate from the applicator and contained in a separate form apart from the applicator, such as a separate tube, vial, pad, patch etc.
  • the body condition can be a medical condition or a cosmetic condition.
  • Representative medical conditions include, but are not limited to, AIDS, breast cancer, melanoma, liver cancer, lung cancer, blood cancer, pituitary tumors, other cancers, flu, infection, blood disease, cardiac disease, back pain, neck pain, body pain, general pain, arthritis, osteoporosis, headache, depression, smoke, alcoholic, overweight and obesity, menopause, facial hair growth, balding, polycystic ovary syndrome, need of inoculation, need of anesthetics and in particular dermal disease.
  • Representative cosmetic conditions include, but are not limited to, skin aging, skin wrinkle, dark spot, skin discoloration, moisturizing, skin lightening, skin whitening, skin firming, skin lifting, acne, acne mark, acne scar, cellulite, wart, infection, irritation, dry skin and oily skin.
  • the applicators of this subject matter are designed as disposable devices, re-usable devices, and/or recyclable devices.
  • the applicators are disposable after one or more uses.
  • the applicator can be recycled by providing a new active agent and/or a new microdevice.
  • the applicator may be sterilized before and/or after each use by using a sterilization method known in the art.
  • the applicators disclosed herein are effective in increasing the skin diffusion of molecules, especially therapeutic molecules with molecular weight higher than 500 Daltons and hydrophilic molecules to transport through the skin barrier. It has been found that the enhancement of percutaneous transport was also observed for small molecules with a molecular weight lower than 500 Daltons, as well as large molecules with a molecular weight higher than 500. Because the height of the microneedles and microblades is limited, it will not reach the nerve-rich dermis layer and cause any discomfort to the subject.
  • Active agents or active substances that can be delivered using the applicator are therapeutic agents and/or cosmetic agents.
  • therapeutic agent is used herein to refer to active agents that can treat, prevent, and/or ameliorate a body condition or skin condition that needs treatment.
  • cosmetic agent is used herein to refer to active agents that can treat, prevent, conceal, and/or ameliorate a cosmetic body condition or skin condition that needs treatment.
  • a list of examples includes, but is not limited to: drugs, vaccines, peptides, proteins, genes, DNAs, nutraceuticals and cosmetics. The drugs can be administered topically and systemically.
  • drugs as active agents include, but are not limited to, antibiotics, hormones, steroids, anti-inflammatory drugs, protein drugs, DNA drugs whether natural or synthesized, such as benzoyl peroxide, azeleic acid and its derivatives, L-carnitine, botulinum toxin, koji acid, arbutin, niacinamide, Recombinant Erythropoietin (rhEPO), Taxol(R), Interferon-alpha-lb, Interferon beta, Interferon gamma, Emla(R), Fluorouracil, Lidocaine, Salicylic acid, Pureriran, eflornithine hydrochloride, spironolactone, flutamide, insulin, nanoparticle drugs, Epidural, recombinant human parathyroid hormone, growth hormone, thyroid, Cortisol, estrogen, progesterone, and testosterone.
  • antibiotics hormones, steroids, anti-inflammatory drugs
  • protein drugs DNA drugs whether natural or synthesized,
  • vaccines active agents include, but are not limited to: vaccine against influenza (flu), diphtheria, tetanus, pertussis (DTaP), measles, mumps, rubella (MMR), hepatitis B, polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.
  • influenza flu
  • diphtheria diphtheria
  • tetanus pertussis
  • MMR rubella
  • hepatitis B polio, haemophilus influenzae type b, chickenpox, tuberculosis, anthrax, yellow fever, rabies, AIDS, cancers, meningococcus, SARS and cholera.
  • cosmetic substances as active agents include, but are not limited to: botulinum toxin type A, hyaluronic acid and its derivatives, acetyl hexapeptide-3, vitamin A, vitamin C and its derivatives, vitamin E, alpha-hydroxyacids, collagen and hormones. Diagnostic reagents are also included. Examples include, but are not limited to, quantum dots, functionalized nanoparticles, and magnetic particles for diagnostic purpose.
  • the active agent is combined with a cosmetic concealer which may conceal a skin blemish.
  • the dosage of the agent can vary according to the medical condition being treated.
  • the effective amount of an agent that has been well established in the art can be publicly available. Such information can be obtained from the U.S. Food and Drug Administration (FDA), e.g., FDA website.
  • FDA U.S. Food and Drug Administration
  • the agent is a pain relieving drug for neuropathic or nociceptive pain management.
  • Such pain relieving drug includes, but is not limited to, Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA(R); Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAEDs such as Celecoxib (Celebrex), rofecoxib (Vioxx), valdecoxib (Bextra); or combinations thereof.
  • the pain relieving drug described herein can specifically exclude any of the drug/agents listed herein.
  • the active agent can be muscle relaxants, which include, but are but are not limited to, Benzodiazepines; Methocarbamol; Carisoprodol; Chlorzoxazone; Metaxalone; Cyclobenzaprine, or combinations thereof.
  • the muscle relaxants described herein can specifically exclude any of the drug/agents listed herein.
  • the present subject matter provides an applicator for delivery of the therapeutic active agent as defined above across the skin barrier, or stratum corneum layer. Once the substances pass the stratum corneum, there is less resistance for the substances to diffuse into the subsequent layers of the skin: epidermis and dermis. The substances will be absorbed by microvessels and lymphatics in the dermis layer and can be delivered to the entire human body. Applicators disclosed in the current subject matter can enhance skin penetration of molecules of a molecular weight lower than 500 Dalton.
  • Applicators can also enable through the skin transport of large molecules of a molecular weight higher than 500 Dalton, as exemplified by Bovine Serum Albumin at 66,000 Dalton, Botulinum Toxin Type A at 150,000 Dalton, and the Interferon- Alpha- lb at 17,000 Dalton.
  • the active agent stored on the applicator is applied to the area of skin being perforated by the microdevice. In many embodiments, the active agent is applied after the skin is perforated by the microdevice. In other embodiments, the active agent is applied to the area of skin being perforated before the skin is perforated by the microdevice.
  • Botulinum Toxin Type A is a toxin that blocks neuromuscular transmission when it is injected in small amounts (e.g., 10 units per 0.1 ml injection volume) into specific muscles to treat and reduce wrinkles on the face.
  • the maximum dosage recommended as a single injection for any one muscle at any spot is 25 units. If overdosed or the injection is incorrectly performed, the patient can be left with an immobile face or droopy eyelids until the effect of the injection wears off. Possible side effects include numbness, swelling and headaches.
  • botulinum toxin type A is applied to the skin pre- treated with the applicator described herein. A significant increase in through the skin penetration of botulinum toxin type A has been observed. No through the skin transport was observed without application of applicators. More examples were provided in the above "active agents" section.
  • hyaluronic acid gel through diffusion enhanced by applicators.
  • Hyaluronic acid is a substance that exists naturally in the body. A major important function of hyaluronic acid is to carry and bind water molecules. Stabilized non-animal hyaluronic acid does not contain animal protein and does not require a skin test prior to treatment. It is thus a preferred embodiment of this subject matter to use applicators to delivery locally stabilized non-animal hyaluronic acid to treat wrinkles and facial lines.
  • Another embodiment of this subject matter is to provide for local delivery of acetyl hexapeptide-3.
  • This molecule is a non- toxic, non-irritant compound that modulates the excessive stimulation of the facial muscles, relaxing facial tension and it can reduce and prevent the formation of new wrinkles due to over-stimulation of facial muscles. More examples include but are not limited to: vitamin A, vitamin C and its derivatives, vitamin E, alpha-hydroxyacids, hormones, or combinations thereof.
  • the applicator provided herein can be used for topical delivery of vaccines below the stratum corneum layer.
  • the type of vaccines includes conventional vaccines as well as protein, peptide, DNA vaccines and the like as previously described.
  • Vaccination can be performed by treating a skin side with the applicator and then delivering a vaccine composition to a user.
  • the applicator described herein can be used for pain management.
  • the applicator can be used to facilitate percutaneous delivery of a pain relieving agent or a combination of them so as to treat, reduce or prevent pain.
  • a skin side can be treated with the applicator and then a pain relieving agent or drug composition can be delivered percutaneously to a user.
  • the pain relieving agent can be any pain relieving agent approved by the FDA or used in medical practice elsewhere in the world.
  • the pain relieving drug can be, but is not limited to, NSAIDs, COX-2 inhibitors, steroids, muscle relaxants.
  • NSAIDs such as Lidocaine; Prilocaine, Tetracaine, Ibuprofen; Acetaminophen; Capsaicin; EMLA(R); Tramadol (Ultram); Gabapentin, Tramadol hydrochloride, Corticosteroids, Sufentanil, Clonidine, Bupivacaine, Tricyclic antidepressants, opioid analgesics such as morphine, Hydromorphone, naloxone (Narcan), Talwin, Nubain, Stadol, Fentanyl, Meperidine, Hydrocodone, Codeine, Oxycodone; non-selective NSAIDs such as Celecoxib (Celebrex), rofecoxib (Vi
  • the pain management can be carried out according to a management regime prescribed by a treating doctor.
  • the pain management is chronic or acute pain management.
  • the pain management regime can be but is not limited to, low back pain, post-herpetic neuralgia, cancer pain, diabetic neuropathy, phantom limb pain, spinal stenosis/sciatica, spinal mets, HIV pain, pain caused by invasive medical procedures such as needle injection, and cannulation.
  • the applicators need to deliver drug molecules through the skin at a rate that is sufficient to maintain a therapeutic useful concentration in plasma.
  • the size and density of the microneedles, microblades, and/or microknives on the microdevice can be adjusted to meet the delivery requirement.
  • the active agent is present in the active agent chamber and applied to the area of skin being perforated after the microdevice is applied to the skin and immediately removed.
  • the active agent is formulated with one or more physiologically acceptable carriers.
  • the active agent formulation may comprise one or more rheology modifiers, surface active agents, stabilizers, rehydration agents, and combinations thereof.
  • hydrogels of the active agent can be prepared using carbomer polymers, including, for example, CP940, CP974, CP980 and CP1342.
  • carbomer polymers including, for example, CP940, CP974, CP980 and CP1342.
  • the special active agent formulation can control the diffusion rate of the active drug molecule and regulate the drug release rate.
  • the applicator may optionally include one or more integrated indicator signal device(s), or built-in non-verbal instructional device(s).
  • a built-in nonverbal instructions device as used herein can refer to a battery powered device with at least one signal emitting or producing element that can be switched on and off according to application specifications.
  • Such devices can produce or provide various signals for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, vibration, RF transmitted signal, recorded counter signal, and/or an electric transmitted signal, or other indicator feature or signal described herein, to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin.
  • the microdevice is located on an actuator arm in the applicator and is applied to the area of skin being perforated. As force is applied to the surface of the microdevice at the skin the microdevice and actuator arm is pushed toward an integrated signal device. When the actuator arm applies sufficient force to the signal device, a force-sensitive switch in the signal device is activated which then triggers a signal.
  • the signal may be any signal that can be detected by the user or by another observer.
  • the signal may be emission of light, sound, vibration, or an electrical signal to a second signaling device, data recorder, user, or observer.
  • the integrated signal device can have a built-in circuit to record the force being applied, the duration of application, and/or the number of accumulated applications to monitor for the expected expiration of the device.
  • the signal of light, sound, and/or vibration can be different based on wavelength, frequency, vibration patterns, a combination thereof, and the like.
  • the amount of force required to activate the signal device will be an amount of force sufficient for the microdevice to perforate the stratum corneum.
  • the amount of force required to activate the signal device can be adjusted by adjusting the signal device switch mechanism and/or actuator arm action. The amount of force required might be adjusted in order to provide more careful and delicate application to softer skin areas (such as, for example, around the eyes) or patients with more sensitive skin (such as, for example, in children or persons with hypersensitive skin).
  • the signal device is switched off when the applicator is removed from the skin as the required force is removed.
  • the signal is a light signal, a sound signal, a vibration signal, or a combination thereof.
  • the signal device is connected to a timer and an event counter to record the duration of time and the number of times the applicator has been applied.
  • the counter may optionally have a second signal device which activates when a pre-specified number of applicator uses has been reached. For example, after a number of pre-specified uses the counter signal might indicate that the applicator should be cleaned, replaced, or discarded. Such a counter may then help ensure the device is in optimal condition for providing the indicated treatment.
  • the microdevices may be fabricated using MEMS microfabrication technology.
  • the typical fabrication process involved lithography, wet etch and dry etch, thin film deposition and growth, electroplating, as well as injection molding and hot embossing.
  • One example of fabrication method was to use Bosch process that allowed deep Si etch (www.oxfordplasma.de/process/sibo-l .htm). It formed microdevices suitable either as device body or mold for further processing and, for example, is described in previous published patent applications.
  • Yet another fabrication method can use HF solution to electrochemically form porous Si structures (www.techfak.uni- kiel.de/matwis/amat/poren/ps.html).
  • Metals can be used for the fabrication of microdevice through a maskless process called electropolishing starting from a structure fabricated by traditional machining methods such as cutting, electro- discharge machining, milling, grinding, polishing and drilling (www.najet.com and www.fischion.com/product support/model 110 application notes. asp).
  • electropolishing starting from a structure fabricated by traditional machining methods such as cutting, electro- discharge machining, milling, grinding, polishing and drilling (www.najet.com and www.fischion.com/product support/model 110 application notes. asp).
  • the applicator described herein can be suitably packaged to permit easy one-press removal of the applicator from the package.
  • the present subject matter can relate to a package for an applicator, comprising: an outer container and an inner packaging material, wherein the inner packaging material comprises an indent shaped to contain an applicator as described herein and a further depression underneath the indent shaped to contain the applicator.
  • the applicator can be placed in an inner packaging material in a package with one end over a depression.
  • the applicator is placed in an indent in the inner packaging material shaped to hold the applicator.
  • the depth of the depression can vary from 2mm to 50 mm.
  • the depression can optionally contain bumps of 1mm to 30 mm therein.
  • the package of the present subject matter preferably comprises an outer container.
  • the outer container can be any container suitable for holding the inner packaging material and the applicator therein.
  • a suitable outer container is a carton.
  • the carton may be made of any suitable material that provides the structural support for holding the first product container and the second product container. Materials useful as the carton include, without limitation, cardboard, paper, metal and plastic.
  • the outer container comprises shrink-wrap.
  • the outer container of the present packaging may also contain an item selected from the group consisting of a single bar code, a single new drug code, and a single universal product code.
  • the inner packaging material may be any material firm enough to hold the applicator in place, yet able to absorb any vibrations to ensure the safety and stability of the applicator (i.e., to ensure that the applicator does not break before it is ready for use.)
  • Non-limiting examples of preferred inner packaging materials in this regard include a shaped foam or carton.
  • FIG. 1 is a schematic view of a first applicator embodiment showing an exploded view of all components.
  • This embodiment includes an optional signal feature for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin.
  • the Active Agent Reservoir and Body 005 has a soft wall. When pressed, gel/lotion/cream contained therein can be squeezed out from the Applicator tip nozzle 006 to an area of skin pretreated with the FMA microdevice and actuator arm 003.
  • the Integrated Signal Device 004 has one ore more of timer, force switch, counter to signal the force applied to skin, time duration of each application and the total accumulated number of applications.
  • FIG. 2 shows schematic views of the first applicator embodiment having a microdevice for painlessly perforating the outer layer of skin and a reservoir of active agent.
  • FIG. 3 shows a schematic view of the first applicator embodiment wherein the FMA microdevice moves the actuator arm when contacting the skin.
  • the actuator arm thereby contacts the pressure sensitive signal device which generates a signal when sufficient force is applied when contacting the skin with the microdevice to perforate the skin.
  • FIG. 4 is a schematic view of a second applicator embodiment showing an exploded view of all components.
  • This embodiment includes an optional signal feature for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin.
  • Component Name & Function is a schematic view of a second applicator embodiment showing an exploded view of all components.
  • This embodiment includes an optional signal feature for verifying compliance with predetermined methods of using the applicator, such as, for example, a light, sound, and/or vibration to indicate that the microdevice has been applied to the skin with the recommended amount of force for perforating the outer layer of skin.
  • the Actuator Arm 011 holds the FMA microdevice 012.
  • Gel/cream/lotion is dispensed from the applicator tip nozzle 002.
  • the Applicator Sleeve cap 002 and Applicator sleeve, active agent chamber 003 form a cavity to hold active agent(s).
  • 002 and 003 are connected with a mechanical lock-in structure to facilitate the filling of active agent(s).
  • the Applicator tip nozzle 005 and Connector 006 are connected using a mechanical structure on the Connector 006.
  • the spiral structure on the Connector 006 pushes the Applicator tip nozzle 005 to move in the direction to push active agent(s) out through the gel nozzles. It moves the Applicator tip nozzle 005, acting like a piston, in the cavity formed by the Applicator sleeve cap 002 and the Applicator sleeve 003.
  • the Dial Ring 008 and the Dial tube 009 are connected with a spring. Each dial of the Dial Ring 008 makes a sound between the Fixed Gear 007 and the Dial Ring 008.
  • the FMA protective sleeve 013 and the Dial tube 009 are connected.
  • FMA microdevice end 014 rotates, the rotation is passed on through the FMA protective sleeve 013 to the Dial tube 009.
  • FIG. 5 shows schematic views of the second applicator embodiment having a microdevice for painlessly perforating the outer layer of skin and a reservoir of active agent.
  • FIG. 6 shows scanning electron microscope micrographs of examples of two different microneedle arrays having different microneedle sizes and density of microneedles. These microneedle arrays are examples of those that may be found on an applicator described herein.
  • FIG. 7 is a perspective illustration showing the depth that the microdevice on the applicator perforates into the skin relative to the stratum corneum (SC), epidermis (Epi), and dermis (Derm), and the subsequent delivery of active agent applied to the area of skin that was perforated via microchannels generated by the microdevice.
  • SC stratum corneum
  • Epi epidermis
  • Derm dermis
  • the use of an applicator of the present subject matter was a simple two-step procedure.
  • the first step was the perforation of skin using the microdevice attached to one end of the applicator, wherein the applicator is held in the hand and physical force is applied so that the microdevice end of the applicator causes the microdevice to perforate the skin.
  • the amount of force applied to perforate the skin is also sufficient to move the actuator arm to contact and activate the switch on the integrated signal device.
  • Activating the signal device resulted in a light to be illuminated.
  • the user detected the light and recognized the light as indicating that the skin has been perforated.
  • the user then immediately removed the applicator and microdevice from the skin.
  • the second step was to apply the active agent to the area of skin perforated by the microdevice.
  • the user then turned the applicator around and applied an active agent formulation from a nozzle attached to that end of the applicator.
  • the active agent is contained in an active agent chamber contained in the body of the applicator.
  • the active agent was applied to the area of skin perforated by the microdevice.
  • the microdevice end was swabbed or immersed in a disinfectant solution or cream. End caps were then placed over both the microdevice region and the applicator nozzle region for storing the applicator.
  • a applicator described herein may be used in pain management.
  • Lidocaine an anesthetic agent
  • Pain management using the applicator provided herein, as compared to prior art, has at least these two advantages: (1) rapid onset, and (2) about ten times improvement in percutaneous drug delivery.
  • a applicator described herein may be used in cosmetic treatment.
  • L-Carnitine is used as the active agent and can penetrate skin 10 times faster on applicator pre-treated skin.
  • Cosmetic cellulite management using the applicator provided herein, as compared to prior art, has at least these two advantages: (1) rapid onset, and (2) about ten times improvement in percutaneous drug delivery.
  • L-carnitine is a naturally occurring compound used by the body to transport long-chain fatty acids across inner mitochondria membrane for ⁇ -oxidation. It is a nutrient essential for energy production and fat metabolism in skeletal muscle and heart [1]. More than 95% of human body's total carnitine is in myocardium and skeletal muscle [2].. In recent years, LC has been extensively used as a medicine in the treatment of carnitine deficiency disorders [3, 4], a variety of cardiovascular symptoms [1, 5] and the prevention of drug-induced myopathies in patients with HIV infection [6]. Furthermore, many researchers found that supplementation of LC have potentially beneficial effects on athlete performance [7], obesity [8], liver healthy [9], hemodialysis [10], male infertility [11] and diabetes [12].
  • LC ((3R)-3-hydroxy-4-trimethylazaniumylbutanoate, MW 161.2 Da), Carbomer 940 P (CP940), Carbomer 974 P (CP974), Carbomer 980 P (CP980) and Carbomer 1342 P (CP 1342) were all purchased from GuoRenYiKang Technology (Beijing, China). HPLC grade methanol was obtained from Dikma Technology (Beijing, China). All solutions were prepared with ultrapure water (resistivity >18 ⁇ /cm). All chemicals used were analytical or pharmaceutical grade.
  • Each FMA has 484 microneedles perpendicular to the wafer, over an area of 10 ⁇ 10 mm 2 .
  • Each microneedle has an octagonal pyramidal shape. They are 150 ⁇ in height, with a base length of about 100 ⁇ , a cone angle of 38° and a needle tip less than lOOnm.
  • the FMA was fixed onto the supporting mechanism of an applicator to form an intradermal drug delivery system, which provided an insertion force of approximately 2 N.
  • Hydrogels of LC were prepared using Carbomer polymers, including- CP940, CP974, CP980 and CP 1342. Briefly, at a concentration of 0.5% (w/w) of Carbomers were added to ultrapure water with vigorous mixing and the dispersion was allowed to hydrate and swell for about 2h. Then the gels were formed by dropwise addition of triethanolamine (0.8% w/w) to neutralization. Finally, appropriate amount of LC powder was dissolved in the above gels with stirring at room temperature.
  • mice Male Sprague-Dawley rats (220-250g) were provided by Beijing Weitong Lihua Experimental Animals Ltd. Co. (Beijing China). Forty-eight hours before the test, rats were anesthetized by ether, and then the abdominal hair of each rat was shaved with an electric hair clipper. At the beginning of in vitro studies, animals were euthanized using carbon dioxide and full-thickness skins were removed. All research protocols adhered to the Guide for the Care and Use of Laboratory Animals (1996).
  • Samples of full-thickness dermatomed human cadaver skins ( ⁇ 800 ⁇ ) were obtained from the Burns Institute, 304 th Clinical Department, The General Hospital of PLA, Trauma Center of Postgraduate Medical College and were free from overt pathology. The skin samples were kept frozen in liquid nitrogen and used within 3 months. Porcine ear skins (adult pig) were purchased from a local slaughterhouse immediately following the animal death and the whole skins were carefully dermatomed to a thickness of 800 ⁇ with skin grafting knife. The excised porcine ear was wrapped in plastic film and stored in liquid nitrogen until use within 3 months.
  • the method of the percutaneous absorption study adheres to the Test Guideline 428 of Organization for Economic Cooperation and Development (2004).
  • the experiment was performed with a system employing Franz-type glass diffusion cells.
  • the temperature in the receptor chamber was maintained at physiological temperature of 37.0 ⁇ 0.1 °C with an external, constant temperature circulating water bath.
  • Skin samples were treated using FMA delivery system.
  • the insertion force was provided by the applicator.
  • the skins without FMA treatment were used as control.
  • the skin was mounted on a receptor chamber (2.5 ml) with the stratum corneum side facing upward into the donor chamber with effective permeation area of 0.66 cm .
  • the receptor and donor chambers were filled with PBS solution, and the receptor fluid was continuously stirred with a magnetic bar at 280 rpm to maintain homogeneity. After 1 h equilibration, the solution in the receptor chamber was replaced with fresh PBS, and 300 ⁇ of LC solution or 300mg of LC gel was applied on the skin in the donor chamber, which was then covered with a parafilm to avoid any evaporation process.
  • mice Male Sprague-Dawley rats (250g ⁇ lOg) were equally divided into four groups (3 for each): group A, B, C and D. Before administration, all rats allowed to acclimatize for one week. One day before administration, rats were fasted overnight but allowed access to water. The hair of abdominal skin was carefully shaved by electric clippers for Group A and B. The rats in group A were pretreated by FMA with an area of 2 cm , the group B was untreated as a control. Then hydrogel patch containing LC 750 mg was applied to each rat by an adhesive housing for 6h. Group C and Group D were control groups of oral and intravenous injection administration of 1 ml LC solution (200 mg/ml). A volume of 0.5 ml blood samples were taken before administration and at predetermined time intervals after LC administration. Plasma samples were immediately separated by centrifugation at 4000 x g for 7mins, and stored at -80 °C until assay.
  • the quantitative determination of LC was performed by HPLC using methanol- 190mM KH 2 P0 4 water (87: 13) as mobile phase at a flow rate of 0.6 ml/min, by LC- 201 OA (Shimadzu, Japan).
  • the injection volume was 20 ⁇ .
  • the analysis was performed in a YMC-Pack ODS-A CI 8 column with dimensions of 250 mm x 4.6 mm i.d., 5 ⁇ particle size (YMC Inc., USA).
  • the column eluant was monitored at 225 nm.
  • the detection limit is 20 ⁇ g ml "1 .
  • the inter- and intra-day variability was less than 5%.
  • Pretreatment method of samples 120 ⁇ of plasma was deproteinized with 600 ⁇ of 0.6 M perchloric acid. The mixture was shaken for 30 s and allowed to stand in an ice bath for about 15 mins. After centrifuged at 4000xg for 7 mins, 500 ⁇ of supernatant was transferred to a new tube in which 300 ⁇ of 0.5 M K 2 C0 3 was added, the mixture was shaken for 30 s and incubated in an ice-bath for 15 mins. Precipitate of KC10 4 was removed by centrifugation at 4000xg for 7 mins, and 200 ⁇ 1 of the supernatant with free LC was separated for the assay. The recovery ratio of LC in plasma was 85 ⁇ 2%.
  • the concentration of free LC in serum was determined by enzymatic assay kit with a limitation detection of 0.8 ⁇ g /ml. (BIOSENTEC France), Cat.No.066.
  • Table 1 shows the permeation rates of LC across different species of skins by passive diffusion or with FMA pretreatment.
  • the permeation rates of LC by FMA were significantly enhanced in all species of skins comparing with passive diffusion.
  • the permeation rate of LC through human skin was enhanced 59 times comparing with passive diffusion and was nearly the same with porcine ear skin, but there were significant differences between human and porcine ear skin by passive diffusion (p ⁇ 0.05).
  • the permeation rates of LC through rat skin was about 13.8 times higher than that of human skin by passive diffusion, and the enhancement was only 3.7 times after FMA-puncture. According to the above results, it was implied that FMA may reduce the interspecies variations in skin permeability.
  • Carbomer polymer At present, numerous grades of Carbomer polymer are commonly available for the percutaneous hydrogel formulations because of their low irritation and high viscosity at low concentration. Different types of Carbomer varying in cross-link density and molecular weight could influence the diffusion pathway and drug release [29].
  • carbomer polymers eg: CP940, CP974, CP980, CP 1342
  • the influence of different carbomer polymers eg: CP940, CP974, CP980, CP 1342
  • FMA FMA
  • LC hydrogel 640 mg/g
  • Figure 10 illustrates the cumulative amount of LC penetrated from the various kinds of Carbomer formulations.
  • Total cumulative amount of LC from CP980 and CP974 were significantly higher than that from CP1342 and CP940 (PO.05). Furthermore, there was no significant difference between the cumulative amount from CP974 (71.78 ⁇ 12.44 mg/cm 2 ) and CP980 (64.43 ⁇ 14.48 mg/cm 2 ) (P>0.05). It was noteworthy that the viscosity of CP980 calculated by rheological synergism was significantly higher than CP974 [30]. Therefore, gel containing CP 980 was elected as a suitable carrier for topical application of LC.
  • the residual content of drug in the patch was investigated to assess the apparent LC dose delivered by applying topical gel formulation CP980 (750 mg/rat) to rats with and without FMA pretreatment.
  • Table 2 presents the mean apparent dose of LC gel patch delivered after 6h topical application with and without FMA pretreatment. About 27 % of initial amount of LC was delivered into rats by FMA pretreatment, totaling 200mg/rat. However, there was no significant difference between the residual and initial content by passive diffusion. These results showed that FMA intradermal delivery successfully allowed much higher apparent dose of LC delivery than traditional percutaneous delivery. It implied that FMA intradermal delivery system could solve the problem of high dose requirement for LC.
  • Figure 1 1 shows the plasma concentration-time profiles of LC after intravenous (200 mg/rat), oral (200 mg/rat) and FMA percutaneous administration (750 mg/rat).
  • the corresponding pharmacokinetic parameters are summarized in Table 3.
  • Table 3 can cause confusion as FMA dose is more than 3 times than that of oral and intravenous. We can say AUC is more than 10 times than that of oral.
  • the plasma concentration was up to 3.90 ⁇ 0.42 mg/mL at 3 min, but rapidly decreased to 0.27 ⁇ 0.05 mg/mL at 2 h.
  • Oral administration brought low plasma levels, and the plasma concentration peaked at 2h (0.040 ⁇ 0.01 1 mg/mL).
  • the absolute bioavailability was 8 %. Comparing with oral administration, higher plasma concentrations were obtained by using FMA intradermal delivery system.
  • the AUCo- ⁇ was 3016 mg.h.L "1 , 10- fold higher than that of oral administration and the absolute bioavailability was 22%.
  • a maximum concentration (C ma x) of 0.53 ⁇ 0.086 mg/mL was achieved at 4h, which was about 13-fold higher than that following oral administration.
  • FMA intradermal delivery administration would provide a new and effective administration strategy for enhancing bioavailability of LC, and potentially improve patient compliance with additional benefits such as controlled stable release of drugs to minimize toxicity while maximizing therapeutic outcome.
  • FMA painless intraepidermal delivery system could be used for percutaneous administration of LC.
  • a 2.8-fold enhancement of absolute bioavailability was obtained comparing with oral administration.
  • FMA intradermal delivery system represents a promising and beneficial method for LC administration and can be possibly extended to other high hydrophilic drugs. Further studies should be conducted to probe the tissue concentration of LC in rat tissues (e.g.: muscle, heart, kidney and liver) by FMA intradermal delivery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur un dispositif pédagogique compact non verbal incorporé pouvant être intégré à un applicateur ayant un micro-dispositif pour une perforation sans douleur de la peau et, de manière facultative, un agent actif stocké dans une première chambre de l'applicateur pour une application sur la zone de la peau qui est perforée. Le micro-dispositif de l'applicateur peut comprendre des micro-aiguilles, des ensembles de micro-aiguilles, des microlames, des ensembles de microlames, des micro-couteaux, des ensembles de micro-couteaux et des Micro-Ensembles Fonctionnels (FMA). Le dispositif pédagogique compact non verbal incorporé vérifie la conformité à des procédés prédéterminés d'utilisation de l'applicateur, tels que, par exemple, une lumière pour indiquer que le micro-dispositif est appliqué sur la peau avec la quantité recommandée de force pour perforer la peau. L'applicateur est utile pour assurer une administration améliorée d'un agent actif pour un traitement thérapeutique ou cosmétique et une administration systémique ou localisée améliorée d'un agent actif, tel que, par exemple, la L-camitine, l'insuline, la toxine botulinique, etc.
EP10848088.0A 2010-03-17 2010-03-17 Dispositif pédagogique non verbal incorporé pouvant être intégré à des applicateurs Active EP2547396B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/000800 WO2011115602A1 (fr) 2010-03-17 2010-03-17 Dispositif pédagogique non verbal incorporé pouvant être intégré à des applicateurs

Publications (3)

Publication Number Publication Date
EP2547396A1 true EP2547396A1 (fr) 2013-01-23
EP2547396A4 EP2547396A4 (fr) 2013-12-18
EP2547396B1 EP2547396B1 (fr) 2019-05-01

Family

ID=44649486

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10848088.0A Active EP2547396B1 (fr) 2010-03-17 2010-03-17 Dispositif pédagogique non verbal incorporé pouvant être intégré à des applicateurs

Country Status (9)

Country Link
US (1) US9149618B2 (fr)
EP (1) EP2547396B1 (fr)
JP (1) JP2013521928A (fr)
KR (1) KR101708966B1 (fr)
CN (1) CN103079634B (fr)
AU (1) AU2010348350B2 (fr)
CA (1) CA2792848C (fr)
SG (1) SG184128A1 (fr)
WO (1) WO2011115602A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144257A1 (fr) 2009-05-26 2010-12-16 The General Hospital Corporation Procédé et appareil pour l'administration dermique d'une substance
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
US9011350B2 (en) 2011-11-30 2015-04-21 Lincoln Diagnostics, Inc. Allergy testing device and method of testing for allergies
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2014058746A1 (fr) 2012-10-10 2014-04-17 3M Innovative Properties Company Applicateur régulé par une force pour appliquer un dispositif à micro-aiguille sur la peau
EP2906285B1 (fr) 2012-10-10 2019-06-12 3M Innovative Properties Company Applicateur d'application d'un dispositif à micro-aiguilles à la peau
CN104797287B (zh) 2012-11-16 2017-12-26 3M创新有限公司 力控施用装置
US20150352295A1 (en) * 2013-01-08 2015-12-10 3M Innovative Properties Company Application For Applying A Microneedle Device To Skin
SG11201507885TA (en) * 2013-03-22 2015-11-27 3M Innovative Properties Co Microneedle applicator comprising a counter assembly
GB201401133D0 (en) 2014-01-23 2014-03-12 Renephra Ltd Fluid extraction device, applicator device and associated methods
WO2015138992A1 (fr) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Administration de 3-bromopyruvate dans les mitochondries
DE102014106170A1 (de) * 2014-05-02 2015-11-05 Roxall Medizin Gmbh Vorrichtung, Einrichtung und Verfahren zum Auf- und Einbringen wenigstens einer Allergen-Testlösung auf und in die Haut eines Körperteils einer zu testenden Person
JP6028063B2 (ja) * 2015-04-30 2016-11-16 ナノメド ディヴァイシーズ， インコーポレイテッド アプリケータに統合可能な内蔵非言語的指示デバイス
KR101584703B1 (ko) * 2015-09-18 2016-01-12 주식회사 지엠홀딩스 피부 및 탈모 치료용 이미용기기
CN106289493B (zh) * 2016-08-29 2018-10-26 中国计量科学研究院 一种高准确度大质量测量装置
EP3315156A1 (fr) * 2016-11-01 2018-05-02 Sanofi-Aventis Deutschland GmbH Dispositifs d'administration de médicaments
JP2020510480A (ja) * 2017-03-01 2020-04-09 ナショナル ユニバーシティ オブ シンガポール マイクロニードルデバイス
US20210353210A1 (en) * 2018-11-08 2021-11-18 MEDIFORM ITALIA S.r.l. Electric device for the skin allergy test
CN109432585B (zh) * 2018-11-08 2021-08-17 中科微针（北京）科技有限公司 微针经皮给药进针器
USD903866S1 (en) * 2019-01-08 2020-12-01 Guangzhou Ekai Electronic Technology Co., Ltd. Microneedling pen
JP2021094146A (ja) 2019-12-16 2021-06-24 ロレアル マイクロニードルシートを使用する美容方法
CN111329833A (zh) * 2020-03-04 2020-06-26 苏州纳生微电子有限公司 一种物理透皮技术在辅助营养补充中的应用
USD919082S1 (en) * 2020-08-26 2021-05-11 Xianlin He Microneedle instrument
CN218685709U (zh) 2021-12-23 2023-03-24 苏州纳生微电子有限公司 微针阵列芯片
FR3135206A1 (fr) 2022-05-05 2023-11-10 L'oreal Processus cosmétique utilisant une feuille de micro-aiguilles
FR3139007A1 (fr) 2022-08-23 2024-03-01 L'oreal Composition convenant pour des traitements cosmétiques de substance kératineuse

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229562A1 (en) * 2005-04-11 2006-10-12 Marsh Ronald W Injection device with secondary reservoir
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6477410B1 (en) 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
EP1341442B1 (fr) 2000-10-13 2005-06-29 Alza Corporation Applicateur a reseau de microlames produisant un impact
DE60332662D1 (de) * 2003-06-13 2010-07-01 Panasonic Elec Works Co Ltd Sonophorese-hautpflegevorrichtung
CN2747883Y (zh) * 2004-05-24 2005-12-28 候贵管 电动喷粉施药器
US20060253079A1 (en) 2005-04-25 2006-11-09 Mcdonough Justin Stratum corneum piercing device
KR20080009305A (ko) 2005-04-29 2008-01-28 코닌클리케 필립스 일렉트로닉스 엔.브이. 멀티-채널 ｔｖ 프로그램들을 수신하기 위한 장치 및 방법
US7713218B2 (en) * 2005-06-23 2010-05-11 Celleration, Inc. Removable applicator nozzle for ultrasound wound therapy device
US20080319370A1 (en) * 2005-11-04 2008-12-25 Acrux Dds Pty Ltd. Method and System for Transdermal Drug Delivery
WO2007064486A1 (fr) * 2005-11-30 2007-06-07 3M Innovative Properties Company Reseaux de microaiguilles et leurs methodes d'utilisation
FR2898268B1 (fr) * 2006-03-07 2009-04-17 Hakim Nacer Batonnet d'application ou de nettoyage, constitue d'au moins un corps tubulaire concu apte a contenir au moins un liquide
WO2008009364A1 (fr) * 2006-07-17 2008-01-24 Euro-Celtique S.A. dispositif applicateur de médicament
US8002737B2 (en) * 2007-10-04 2011-08-23 Hyprotek, Inc. Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229562A1 (en) * 2005-04-11 2006-10-12 Marsh Ronald W Injection device with secondary reservoir
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011115602A1 *

Also Published As

Publication number Publication date
CA2792848C (fr) 2017-07-04
WO2011115602A1 (fr) 2011-09-22
EP2547396B1 (fr) 2019-05-01
SG184128A1 (en) 2012-10-30
CA2792848A1 (fr) 2011-09-22
KR101708966B1 (ko) 2017-02-21
CN103079634A (zh) 2013-05-01
US9149618B2 (en) 2015-10-06
US20130053752A1 (en) 2013-02-28
KR20130054947A (ko) 2013-05-27
EP2547396A4 (fr) 2013-12-18
AU2010348350B2 (en) 2015-12-03
AU2010348350A1 (en) 2012-10-04
JP2013521928A (ja) 2013-06-13
CN103079634B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
AU2010348350B2 (en) A built-in non-verbal instructional device integratable to applicators
Duarah et al. Recent advances in microneedle-based drug delivery: Special emphasis on its use in paediatric population
Bhatnagar et al. Microneedles in the clinic
Bariya et al. Microneedles: an emerging transdermal drug delivery system
US8043250B2 (en) High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
Jijie et al. Nanomaterials for transdermal drug delivery: beyond the state of the art of liposomal structures
EP2099436B1 (fr) Micro-dispositif et procédé d'administration et de prélèvement transdermique de substances actives
EP2056921B1 (fr) Micro-dispositifs à rapport dimensionnel élevé pour administration transdermique et échantillonnage de substances actives
Prausnitz et al. Transdermal drug delivery
US8048017B2 (en) High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US20050261632A1 (en) High-Aspect-Ratio Microdevices and Methods for Transdermal Delivery and Sampling of Active Substances
Bala et al. Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery
US10525246B2 (en) Microdevice and method for transdermal delivery and sampling of active substances
Singh et al. Microporation techniques for enhanced delivery of therapeutic agents
Pahal et al. Microneedles for extended transdermal therapeutics: a route to advanced healthcare
Herwadkar et al. An update on the application of physical technologies to enhance intradermal and transdermal drug delivery
Grice et al. Electrical and physical methods of skin penetration enhancement
Jain et al. Transdermal Drug Delivery
WO2015148688A1 (fr) Dispositif de transport de masse de type piston pour l'administration par voie dermique et transdermique d'une composition liquide ou solide
JP6028063B2 (ja) アプリケータに統合可能な内蔵非言語的指示デバイス
Stoeber et al. Microneedling in Clinical Practice
Butola A review article on transdermal drug delivery system based on-microneedles
Nguyen Microneedles: The Future of Drug Delivery
Rathor et al. Advancement in transdermal drug delivery system: Microneedles
Anusha et al. TRANSDERMAL DRUG DELIVERY SYSTEM–MICRONEEDLES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20131120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61N 1/30 20060101AFI20131114BHEP

17Q First examination report despatched

Effective date: 20150617

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010058654

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61N0001300000

Ipc: A61B0017200000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 50/30 20130123ALI20181012BHEP

Ipc: A61B 17/00 20060101ALI20181012BHEP

Ipc: A61M 37/00 20060101ALI20181012BHEP

Ipc: A61B 90/00 20130123ALI20181012BHEP

Ipc: A61B 17/20 20060101AFI20181012BHEP

Ipc: A61K 9/06 20060101ALI20181012BHEP

Ipc: A61K 9/00 20060101ALI20181012BHEP

INTG Intention to grant announced

Effective date: 20181114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/06 20060101ALI20181012BHEP

Ipc: A61B 50/30 20160101ALI20181012BHEP

Ipc: A61M 37/00 20060101ALI20181012BHEP

Ipc: A61B 17/20 20060101AFI20181012BHEP

Ipc: A61K 9/00 20060101ALI20181012BHEP

Ipc: A61B 17/00 20060101ALI20181012BHEP

Ipc: A61B 90/00 20160101ALI20181012BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 17/20 20060101AFI20181012BHEP

Ipc: A61K 9/06 20060101ALI20181012BHEP

Ipc: A61B 50/30 20160101ALI20181012BHEP

Ipc: A61K 9/00 20060101ALI20181012BHEP

Ipc: A61B 17/00 20060101ALI20181012BHEP

Ipc: A61B 90/00 20160101ALI20181012BHEP

Ipc: A61M 37/00 20060101ALI20181012BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1125857

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010058654

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010058654

Country of ref document: DE

Representative=s name: WESTPHAL, MUSSGNUG & PARTNER PATENTANWAELTE MI, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602010058654

Country of ref document: DE

Owner name: NANOMED SKINCARE, INC., CUPERTINO, US

Free format text: FORMER OWNER: NANOMED DEVICES, INC., SLINGERLANDS, NY, US

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190501

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190801

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190802

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1125857

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010058654

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

26N No opposition filed

Effective date: 20200204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200317

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190501

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240322

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240329

Year of fee payment: 15

Ref country code: FR

Payment date: 20240320

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240424

Year of fee payment: 15